180 related articles for article (PubMed ID: 17650444)
21. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
Seki R; Ohshima K; Fujisaki T; Uike N; Kawano F; Gondo H; Makino S; Eto T; Moriuchi Y; Taguchi F; Kamimura T; Tsuda H; Ogawa R; Shimoda K; Yamashita K; Suzuki K; Suzushima H; Tsukazaki K; Higuchi M; Utsunomiya A; Iwahashi M; Imamura Y; Tamura K; Suzumiya J; Yoshida M; Abe Y; Matsumoto T; Okamura T
Cancer Sci; 2009 Oct; 100(10):1842-7. PubMed ID: 19656156
[TBL] [Abstract][Full Text] [Related]
22. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
23. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.
Casulo C; Byrtek M; Dawson KL; Zhou X; Farber CM; Flowers CR; Hainsworth JD; Maurer MJ; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW
J Clin Oncol; 2015 Aug; 33(23):2516-22. PubMed ID: 26124482
[TBL] [Abstract][Full Text] [Related]
24. The H/R FcγRIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population.
Levy D; Bellesso M; Oliveira-Souza P; Maciel FV; Pereira J; Bydlowski SP
Clinics (Sao Paulo); 2011; 66(5):919-22. PubMed ID: 21789402
[No Abstract] [Full Text] [Related]
25. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.
Overman MJ; Feng L; Pro B; McLaughlin P; Hess M; Samaniego F; Younes A; Romaguera JE; Hagemeister FB; Kwak L; Cabanillas F; Rodriguez MA; Fayad LE
Ann Oncol; 2008 Mar; 19(3):553-9. PubMed ID: 18083690
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
Cartron G; Dacheux L; Salles G; Solal-Celigny P; Bardos P; Colombat P; Watier H
Blood; 2002 Feb; 99(3):754-8. PubMed ID: 11806974
[TBL] [Abstract][Full Text] [Related]
27. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.
van Oers MH; Tönnissen E; Van Glabbeke M; Giurgea L; Jansen JH; Klasa R; Marcus RE; Wolf M; Kimby E; Vranovsky A; Holte H; Hagenbeek A; van der Reijden BA
J Clin Oncol; 2010 May; 28(13):2246-52. PubMed ID: 20368567
[TBL] [Abstract][Full Text] [Related]
28. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
Galimberti S; Marasca R; Caracciolo F; Fazzi R; Papineschi F; Benedetti E; Guerrini F; Morabito F; Oliva E; Di Renzo N; Federico M; Petrini M; Torelli G;
Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307
[TBL] [Abstract][Full Text] [Related]
29. Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma.
Andersen NS; Donovan JW; Zuckerman A; Pedersen L; Geisler C; Gribben JG
Exp Hematol; 2002 Jul; 30(7):703-10. PubMed ID: 12135667
[TBL] [Abstract][Full Text] [Related]
30. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
[TBL] [Abstract][Full Text] [Related]
31. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ; Heffner LT; Langston AA; Lechowicz MJ; Lonial S; Flowers CR
Br J Haematol; 2015 Nov; 171(4):539-46. PubMed ID: 26248505
[TBL] [Abstract][Full Text] [Related]
33. Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.
Ternant D; Hénin E; Cartron G; Tod M; Paintaud G; Girard P
Br J Clin Pharmacol; 2009 Oct; 68(4):561-73. PubMed ID: 19843059
[TBL] [Abstract][Full Text] [Related]
34. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
Howard OM; Gribben JG; Neuberg DS; Grossbard M; Poor C; Janicek MJ; Shipp MA
J Clin Oncol; 2002 Mar; 20(5):1288-94. PubMed ID: 11870171
[TBL] [Abstract][Full Text] [Related]
35. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
36. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission.
Freedman AS; Gribben JG; Neuberg D; Mauch P; Soiffer RJ; Anderson KC; Pandite L; Robertson MJ; Kroon M; Ritz J; Nadler LM
Blood; 1996 Oct; 88(7):2780-6. PubMed ID: 8839876
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
38. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
39. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.
Procházka V; Papajík T; Faber E; Raida L; Kapitáňová Z; Langová K; Prouzová Z; Jarošová M; Indrák K
Leuk Lymphoma; 2014 Jul; 55(7):1584-90. PubMed ID: 24180329
[TBL] [Abstract][Full Text] [Related]
40. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.
Czuczman MS; Grillo-López AJ; McLaughlin P; White CA; Saleh M; Gordon L; LoBuglio AF; Rosenberg J; Alkuzweny B; Maloney D
Ann Oncol; 2001 Jan; 12(1):109-14. PubMed ID: 11249036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]